238 related articles for article (PubMed ID: 23973117)
1. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.
Endris V; Penzel R; Warth A; Muckenhuber A; Schirmacher P; Stenzinger A; Weichert W
J Mol Diagn; 2013 Nov; 15(6):765-75. PubMed ID: 23973117
[TBL] [Abstract][Full Text] [Related]
2. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
[TBL] [Abstract][Full Text] [Related]
3. [Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing].
Zhang HP; Ruan L; Zheng LM; Bai DY; Zhang HF; Liao YQ; Ding Y
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):28-32. PubMed ID: 23648296
[TBL] [Abstract][Full Text] [Related]
4. Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue.
Fassunke J; Haller F; Hebele S; Moskalev EA; Penzel R; Pfarr N; Merkelbach-Bruse S; Endris V
Int J Mol Med; 2015 Nov; 36(5):1233-43. PubMed ID: 26352389
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples.
Hlinkova K; Babal P; Berzinec P; Majer I; Mikle-Barathova Z; Piackova B; Ilencikova D
Diagn Mol Pathol; 2013 Jun; 22(2):70-5. PubMed ID: 23628817
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
[No Abstract] [Full Text] [Related]
7. Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors.
Leary AF; Castro DG; Nicholson AG; Ashley S; Wotherspoon A; O'Brien ME; Popat S
Eur J Cancer; 2012 Jan; 48(1):61-7. PubMed ID: 22036089
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
[TBL] [Abstract][Full Text] [Related]
9. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.
Smith GD; Chadwick BE; Willmore-Payne C; Bentz JS
J Clin Pathol; 2008 Apr; 61(4):487-93. PubMed ID: 17908804
[TBL] [Abstract][Full Text] [Related]
10. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G
Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
13. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
[TBL] [Abstract][Full Text] [Related]
14. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
[TBL] [Abstract][Full Text] [Related]
15. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.
Isaka M; Serizawa M; Kenmotsu H; Koh Y; Takahashi S; Maniwa T; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Yamamoto N; Takahashi T; Ohde Y
Clin Lung Cancer; 2017 Sep; 18(5):519-526.e1. PubMed ID: 28057436
[TBL] [Abstract][Full Text] [Related]
17. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
König K; Peifer M; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Stamm K; Ueckeroth F; Vollbrecht C; Bos M; Gardizi M; Scheffler M; Nogova L; Leenders F; Albus K; Meder L; Becker K; Florin A; Rommerscheidt-Fuss U; Altmüller J; Kloth M; Nürnberg P; Henkel T; Bikár SE; Sos ML; Geese WJ; Strauss L; Ko YD; Gerigk U; Odenthal M; Zander T; Wolf J; Merkelbach-Bruse S; Buettner R; Heukamp LC
J Thorac Oncol; 2015 Jul; 10(7):1049-57. PubMed ID: 26102443
[TBL] [Abstract][Full Text] [Related]
18. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.
Hu C; Liu X; Chen Y; Sun X; Gong Y; Geng M; Bi L
Oncol Rep; 2012 Nov; 28(5):1815-21. PubMed ID: 22923193
[TBL] [Abstract][Full Text] [Related]
19. High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S; Lee J; Hong ME; Do IG; Kang SY; Ha SY; Kim ST; Park SH; Kang WK; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim DH; Kim KM
PLoS One; 2014; 9(11):e111693. PubMed ID: 25372287
[TBL] [Abstract][Full Text] [Related]
20. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?
Kim ST; Jung HY; Sung JS; Jo UH; Tanaka T; Hagiwara K; Park KH; Shin SW; Kim JS; Kim YH
Am J Clin Oncol; 2013 Feb; 36(1):57-63. PubMed ID: 22237146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
